Allogene Therapeutics Inc.’s decision to preferentially pursue first-line treatment of large B-cell lymphoma (LBCL) with CAR T cemacabtagene ansegedleucel (cema-cel, previously known as ALLO-501A) met mixed reviews on Wall Street.
Allogene makes bold pivot, stopping pivotal trials in pursuit of first-line CAR-T cures fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Presentation Operator MessageOperator Hello. Thank you for standing by, and welcome to the Allogene Therapeutics 2024 Platform vision Conference Call. [Operator Instructions] Please be aware that.
Allogene stock drops on pipeline shakeup (NASDAQ:ALLO) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.